Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab or Good's syndrome?
IntroductionRituximab (RTX) showed good efficacy and safety for patients with myasthenia gravis. However, the percentage of peripheral CD20+ B cell may be absent for years after low dose of RTX treatment. Persistent hypogammaglobulinemia and opportunistic infection may occur in patients under treatm...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2023-05-01
|
| シリーズ: | Frontiers in Neurology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1152992/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|